ESMO pre-"research" news Pabolizumab combined with axitinib in the treatment of metastatic renal cell carcinoma efficacy and safety exploration

Edited and sorted out by Yimaitong, please do not reprint
without authorization.

The 2022 European Society for Internal Oncology (ESMO) Annual Meeting will be held
in Paris from September 9 to 13 local time.

background

The combination regimen of pabolizumab and axitinib (PAXI) is approved as a first-line treatment
for metastatic renal cell carcinoma (mRCC).

method

The ProPAXI study was a multicenter, prospective study that included Italian patients
diagnosed with mRCC who received PAXI as a first-line treatment.

outcome

Between January 2021 and April 2022, a total of 96 patients
were included in the study.

At the time of the analysis, 70% of patients were still receiving treatment, and 65% of patients were still receiving pabolizumab and axitinib
.

About half (57%) of patients experienced clinically significant adverse events (AEs) defined as events
that led to the need for corticosteroids (29%), hormone replacement (11%), delayed use (71%), discontinuation (16%), and dose reduction (36%).

References:

A.
Guida, et al.
Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study).
2022 ESMO.
Abstract 1469P.